September 16, 2019 8:57am

Risk could heighten if higher oil prices slow the manufacturing sector and the Hong Kong disorder continues

Who knows which way will pricing response will be in this market and the latest effect of geo-politics in this market

News: Alnylam Pharmaceuticals (ALNY) has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin amyloidosis (ATTR amyloidosis) with cardiomyopathy. The primary endpoint is the change from baseline in the 6-minute walk test (6-MWT) at 12 months. Secondary endpoints will evaluate the efficacy of patisiran on quality of life using the Kansas City Cardiomyopathy Questionnaire Overall Summary, and composite endpoints of mortality and hospitalization.

My version of the morning’s numbers is written to be informative than just about changes to fundamentals; it’s what happened or will beyond the headline and what could happen to the future

 

Timely insights have line extensions within or to a volatile pricing universe. Thus my line in writing is separating actionable numbers or intelligence and news into a short-term investment thesis to tackle the “unknown unknowns”

 

Dow futures are DOWN -0.34% (-92 points), S&P futures are DOWN -0.33% (-10 points) and NASDAQ futures are also DOWN -0.53% (-42 points)

 

U.S. stock futures dropped Monday morning amid fears that a surge in oil prices following an attack in Saudi Arabia could slow down global economic growth;

European stocks traded lower Monday as investors digested an escalation of tensions in the Middle East following an attack on Saudi oil production;

Asian stocks were mixed after data revealed Chinese industrial output for August grew at its slowest pace for 17.5 years.

 

Henry’omics:

Bottom line, higher oil prices could lead to increasing fuel prices. This would put more pressure on a global economy that is already coping with a slowing manufacturing sector and stubbornly low growth.

 

Any which way but, where?

 

From Friday’s evening post, “equities fell, not as far but, still down … As the NASDAQ struggled. Trade, IP and tariffs resolution is all about saving “face”; the real issue in alleviating the “war” of barbs and words.”

•             The NASDAQ was down -17.75 or -0.22% to 8,176.71;

•             The IBB closed up +0.05% while the XBI also closed down -0.23%;

•             The close was negative with an A/D Line of 18/22 and 3 flats and 2 acquired;

•             The range of the 18 upside was +0.40% (CLBS) to +8.25% (HSGX +$0.017) while the 22 downside ranged from -0.21% (BMRN) to -5.41% (ONVO);

•             5 out of the 18 upside had higher than the 3 month average volume;

•             6 out of the 22 downside had higher than the 3 month average volume;

Q3/19 to date:

  • In July, there were 9 positive, 1 holiday and 13 negative closes;
  • In August there had been 12 negative and 10 positive closes
  • In September there has been 5 positive, 1 holiday and 4 negative close

 

Companies in my headlights – It’s your decision; I provide an idea and context:

*** Just another wait and see morning session***

 

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.